Compare DoorDash Inc (DASH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs TG Therapeutics Inc — how do they compare? DoorDash Inc trades at $212.03 (market cap $91.86B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: DoorDash Inc is far larger — about 12× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| DASH | TGTX | |
|---|---|---|
Market Cap | $91.86B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $59.06 |
52-Week Low | $146.60 | $26.94 |
Enterprise Value | $89.82B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $212.24, up 1.13% today, with a bullish technical outlook as it trades near resistance at $215. The company reported strong revenue growth of 36% year-over-year in Q2 2026 to $4.45 billion, though earnings of $0.46 per share missed estimates due to higher R&D costs. Recent news highlights strategic moves like reincorporation in Nevada and insider selling by a director.
The outlook remains positive with a consensus price target of $247.41, representing 16.6% upside, supported by 76% analyst buy ratings. Key risks include execution on AI and autonomous delivery investments, competitive pressures, and margin compression from rising costs. Revenue growth and expanding market share present the primary investment opportunity.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
